Utilizing genomic polymorphisms to personalize hepatitis C therapies

Area of Science:

• Hepatology
• Genetics
• Pharmacogenomics

Background:

• Hepatitis C virus (HCV) infection often necessitates liver transplantation.
• Antiviral treatment is crucial for managing HCV, but host genetic factors influence treatment efficacy and adverse effects.
• Genomic variations play a role in predicting treatment response and neuropsychiatric adverse events in HCV patients undergoing antiviral therapy.

Purpose of the Study:

• To review the impact of host genomic variations on antiviral treatment response in hepatitis C virus (HCV) infection.
• To identify genetic markers that predict treatment efficacy and the risk of neuropsychiatric adverse effects, particularly depression.
• To inform personalized treatment strategies for HCV patients.

Main Methods:

• Review of recent studies on host genomic variations and HCV treatment.
• Analysis of polymorphisms in genes such as IFNAR1 and IL28B.
• Correlation of genetic variations with treatment response and adverse events like depression.

Main Results:

• Antiviral treatments (pegylated IFN-alpha and ribavirin) show variable response rates, particularly in HCV genotype 1, and are associated with depression.
• Polymorphisms in the IFNAR1 gene promoter influence the risk of depression.
• Polymorphisms in the IL28B gene (encoding IFN-λ-3) are linked to a two- to three-fold improvement in treatment response.

Conclusions:

• Genomic variations in specific genes can predict depression risk and virus clearance likelihood in HCV patients on antiviral treatment.
• Identifying patients at higher risk for depression allows for targeted prophylactic interventions, such as antidepressants or psychotropics.
• Personalized genetic profiling can optimize HCV treatment by predicting outcomes and mitigating adverse effects.